Mark D. Rothmann

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MathematicsEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek”.

Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek

Clinical Trials(2023)10.1177/17407745231169692

N/A

0DataRank · unranked

7 citations

Mark D. Rothmann, Thomas R. Fleming, Lisa M. McShane

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events

Statistics in Medicine(2025)10.1002/sim.70104

N/A

0DataRank · unranked

11 citations

Kevin J. Carroll, Janet Wittes, Scott S. Emerson, Mark D. Rothmann, Sylva H. Collins +2 more